The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
The assays are for diagnosing hepatitis B infection in individuals with acute or chronic hepatitis B, or who are recovering from hepatitis B infection.
Johns Hopkins researchers have developed a proof-of-concept test for research use that they hope to eventually refine for clinical use at the point of care.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
The firm launched the service in part because it recognized that consumers increasingly prefer to pay for their healthcare services out of pocket and without having to get physician referrals.
